LINK PHARMA CHEM LTD. is a Chemicals & Petrochemicals company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 54 | 39 | 30 | 25 | 27 |
| EBITDA (ex other income) | 4 | 3 | (1) | 0 | 1 |
| margin % | 6.6 | 7.0 | (2.2) | 0.5 | 5.3 |
| Owners' profit | 2 | 1 | (1) | (1) | 0 |
| EPS, as reported (₹) | 4.24 | 1.47 | (3.07) | 2.31 | 0.17 |
| ROE % · ROCE % | 13.0 · 16.7 | 4.3 · 9.2 | (9.9) · (7.0) | (8.1) · (4.7) | 0.6 · 4.8 |
| Debt / equity (x) | 0.44 | 0.58 | 0.67 | 0.46 | 0.57 |
| Cash from operations | (1) | (2) | (0) | 3 | 2 |
| Capex | (1) | (1) | (1) | (0) | (2) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 5 | 5 | 6 | 8 | 6 | 7 | 7 | 9 |
| Profit before tax | (0) | (1) | (0) | 1 | 0 | 0 | (0) | 0 |
| Net profit | (0) | (1) | (0) | 0 | 0 | 0 | (0) | 0 |
| EPS (₹) | (0.69) | (1.50) | 0.79 | 0.91 | 0.03 | 0.15 | 0.92 | 0.72 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| DEEPAK FERTILIZERS & PETR | 16,727 | 17.0 | 2.24 | 12.2 | 9.9 | 8.4 | 14.6 | 26.1 |
| TATA CHEMICALS LTD | 15,683 | — | 0.71 | 141.2 | (7.7) | (5.0) | 7.4 | 14.4 |
| GUJ NAR VAL FER & CHEM L | 8,273 | 8.0 | 0.91 | 6.0 | 8.9 | 10.3 | 8.7 | 22.1 |
| TANFAC INDUSTRIES LTD. | 6,773 | 55.4 | 18.15 | — | 18.8 | 24.3 | — | 16.0 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 20 Aug 2026 · Re-appointment of Mr. Satish G. Thakur as Chairman and Whole-time Director for 3 years | management changes | medium | — | — |
| 20 Aug 2026 · Re-appointment of Rishikesh Thakur as Managing Director for 3 years | management changes | high | — | — |
| 20 Aug 2026 · All 6 resolutions passed at 41st AGM with over 99.7% approval | board shareholder meetings | low | — | — |
| 20 Aug 2026 · All 6 resolutions passed at 41st AGM with 99.74% majority | board shareholder meetings | low | — | — |
| 20 Aug 2026 · Link Pharma Chem holds 41st AGM on Aug 20; six resolutions tabled | board shareholder meetings | low | — | — |
| 6 Aug 2026 · Link Pharma Chem Q1 FY27 results: Revenue down 16 percent YoY at Rs 673.62 lakh | compliance | minimal | — | — |
| 5 Aug 2026 · Q1 FY27 results: Revenue up 12% YoY at Rs 8.77 cr, PAT at Rs 31.83 lakh | results | high | — | — |
| 5 Aug 2026 · Board approves Q1 FY27 results: revenue up 12% YoY, profit falls 21% | results | high | — | — |
| 28 Jul 2026 · Annual Report 2025-26 web link sent; 41st AGM on 20 August 2026 | compliance | minimal | — | — |
| 28 Jul 2026 · Notice of 41st AGM, e-voting and book closure | compliance | minimal | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions |
| GUJARAT ALKALIES & CHEM |
| 5,179 |
| 78.0 |
| 1.00 |
| 10.7 |
| (0.0) |
| 0.7 |
| 12.4 |
| 18.4 |
| GHCL LIMITED | 3,879 | 8.4 | 1.09 | 5.1 | 13.3 | 16.6 | 1.1 | 23.9 |
| GRAUER & WEIL IND LTD | 3,469 | 21.2 | 3.21 | 14.1 | 15.2 | 19.2 | 14.5 | 20.4 |
| J.G.CHEMICALS LIMITED | 2,330 | 31.0 | 4.31 | 23.7 | 12.7 | 16.9 | — | 11.5 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 14.3 | 17.0 | 24 of 57 | 59% |
| P/B | 0.9 | 1.4 | 17 of 59 | 69% |
| ROCE | 1.0 | 6.2 | 47 of 65 | 28% |
| ROE | 0.6 | 4.9 | 49 of 65 | 25% |
| Debt / Equity | 0.6 | 0.2 | 47 of 65 | 28% |
| EBITDA margin | 9.2 | 13.3 | 36 of 58 | 39% |
| Revenue growth | 12.2 | 6.7 | 22 of 54 | 60% |
| Profit growth | (20.8) | 21.0 | 44 of 64 | 32% |
| Market cap | 12 | 77 | 57 of 65 | 13% |
| an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
